XML 28 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes) | 9 Months Ended
--- | ---
Jul. 31, 2025
Goodwill and Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS | GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the nine months ended July 31, 2025:
| Life Sciences and Diagnostics Markets |  | Agilent CrossLab |  | Applied Markets |  | Total
| (in millions)
Goodwill as of October 31, 2024 | $ | 3,000 |  |  | $ | 1,168 |  |  | $ | 309 |  |  | $ | 4,477 |
Foreign currency translation impact | 3 |  |  | — |  |  | — |  |  | 3 |
Goodwill arising from acquisitions and adjustments | (5) |  |  | — |  |  | — |  |  | (5) |
Goodwill as of July 31, 2025 | $ | 2,998 |  |  | $ | 1,168 |  |  | $ | 309 |  |  | $ | 4,475 |
In the first quarter of fiscal year 2025, we reorganized our operating segments; see Note 17, "Segment Information" for more information about our segment reorganization. As a result, we used the relative fair value allocation approach to reassign $1.274 billion of goodwill from our Applied Markets segment (formerly Life Sciences and Applied Markets segment) to our Agilent CrossLab and Life Sciences and Diagnostics Markets segments (formerly Diagnostics and Genomics segment). Of the $1.274 billion goodwill reallocated, $365 million was reassigned to our Life Sciences and Diagnostics Markets segment and $909 million was reassigned to our Agilent CrossLab segment. Goodwill balances as of October 31, 2024 have been recast to conform to this new presentation. As a result of the reorganization, our reporting units are: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. In addition, we performed a quantitative goodwill impairment test, and the results of the analysis indicated that the fair values for all three of our reporting units were in excess of their carrying values by substantial amounts; therefore, no impairment was indicated. The component parts of other intangible assets as of October 31, 2024 and July 31, 2025 are shown in the table below:
| Other Intangible Assets
| Gross Carrying Amount |  | Accumulated Amortization |  | Net Book Value
| (in millions)
As of October 31, 2024 |  |  |  |  |
Purchased technology | $ | 1,484 |  |  | $ | 1,169 |  |  | $ | 315 |
Trademark/Tradename | 199 |  |  | 174 |  |  | 25 |
Customer relationships | 291 |  |  | 107 |  |  | 184 |
Backlog | 9 |  |  | — |  |  | 9 |
Third-party technology and licenses | 33 |  |  | 19 |  |  | 14 |
Total intangible assets | $ | 2,016 |  |  | $ | 1,469 |  |  | $ | 547 |
As of July 31, 2025 |  |  |  |  |
Purchased technology | $ | 1,483 |  |  | $ | 1,220 |  |  | $ | 263 |
Trademark/Tradename | 199 |  |  | 179 |  |  | 20 |
Customer relationships | 293 |  |  | 126 |  |  | 167 |
Backlog | 9 |  |  | 2 |  |  | 7 |
Third-party technology and licenses | 34 |  |  | 22 |  |  | 12 |
Total intangible assets | $ | 2,018 |  |  | $ | 1,549 |  |  | $ | 469 |
During the nine months ended July 31, 2025, we recorded measurement period adjustments to decrease goodwill by $5 million primarily to reduce other liabilities and to increase other intangible assets by $2 million related to our acquisition of BIOVECTRA. During the nine months ended July 31, 2025, there was no change in other intangible assets due to the impact of foreign currency. In general, for U.S. federal tax purposes, goodwill from asset purchases is amortizable; however, any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. During the three and nine months ended July 31, 2025, we did not identify any triggering events or circumstances which would indicate an impairment of goodwill or indefinite-lived intangible assets. During the three months ended July 31, 2024, we did not identify any triggering events or circumstances which would indicate an impairment of indefinite-lived intangible assets. During the nine months ended July 31, 2024, we recorded an impairment of in-process research and development of $6 million in research and development in the condensed consolidated statement of operations related to a project in our Applied Markets segment. During the three and nine months ended July 31, 2024 we did not identify any triggering events or circumstances which would indicate an impairment of goodwill. For the three and nine months ended July 31, 2025, amortization expense of intangible assets was $26 million and $81 million, respectively. For the three and nine months ended July 31, 2024, amortization expense of intangible assets was $25 million and $78 million, respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2025 and for each of the next five fiscal years and thereafter is estimated below:
Estimated future amortization expense: |
(in millions) |
Remainder of 2025 | $ | 24 |
2026 | $ | 75 |
2027 | $ | 72 |
2028 | $ | 65 |
2029 | $ | 61 |
2030 | $ | 52 |
Thereafter | $ | 120 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration